Results 211 to 220 of about 204,978 (241)

Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies

Molecular Immunology, 1991
To investigate the IL-6/IL-6 receptor system, we obtained five murine monoclonal antibodies against human IL-6, which neutralize its biological activity. We classified them into two groups (Type I mAb and Type II mAb) according to the epitopes they recognized. These two types of antibodies showed no difference in the manner in which they neutralized IL-
T, Shimamura, S, Taki, H, Honda, M, Yokota, S, Ito, Y, Takahara   +5 more
openaire   +2 more sources

Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn’s disease

Journal of Gastroenterology, 2002
To assess the contribution of IL-6 signaling to the physiopathology of Crohn's disease, we introduced anti-IL-6 receptor monoclonal antibody to a murine colitis model.Colitis was induced in C.B-17-scid mice to which were transferred CD45RBhigh CD4+ T cells from Balb/c mice.
Hiroaki, Ito, Tomonori, Hirotani, Mitsunari, Yamamoto, Hiroyuki, Ogawa, Tadamitsu, Kishimoto   +4 more
openaire   +2 more sources

[Hope for chronic inflammatory diseases : the anti-IL-6 receptor monoclonal antibody tocilizumab].

Revue medicale suisse, 2018
Vasculitis like Horton's disease, some autoinflammatory syndromes (Behcet's, Still's diseases) often require long term treatment with steroids, and therefore are associated with non acceptable adverse events, especially when resistant to treatment. Recently, a number of controlled prospective clinical trials are supporting the interest of the anti-IL-6
openaire   +1 more source

Efficacy of a Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody Compared to Hemoperfusion in Severe COVID-19 Pneumonia: Ambispective Cohort Study

Journal of the American Society of Nephrology, 2022
Kanin Thammavaranucupt, Kulapong Jayanama, Ittikorn Spanuchart   +2 more
openaire   +1 more source

Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis.

Journal of clinical pharmacology
Relationships between tocilizumab exposure and response were evaluated using data from 4 phase III studies. Increased tocilizumab exposure was associated with improvements in Disease Activity Score using 28 joints (DAS28) and American College of Rheumatology (ACR) criteria and with a decrease in inflammation markers.
Micha, Levi, Susan, Grange, Nicolas, Frey   +2 more
openaire   +1 more source

Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes apoptosis in experimental murine colitis

Digestive and Liver Disease, 2000
H. Ito, M. Yamamoto, H. Ogawa, T. Kishimoto   +3 more
openaire   +1 more source

Faculty Opinions recommendation of Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2009
David Scott, Margaret Ma
openaire   +2 more sources

AOSP37 HUMANISED ANTI-VEGF AND ANTI-IL-6 RECEPTOR MONOCLONAL ANTIBODY SUPPRESSED IN-VIVO FLUID RETENTION IN PRIMARY EFFUSION LYMPHOMA

European Journal of Cancer, 2013
H. Goto, E. Kudo, M. Taura, K. Matuda, R. Kariya, S. Okada   +5 more
openaire   +1 more source

Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody, Treatment of neuromyelitis optica spectrum disorders

Case Medical Research, 2019
openaire   +1 more source

Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody (satralizumab), Treatment of neuromyelitis optica spectrum disorders

Case Medical Research, 2019
openaire   +1 more source